The reiteration of an Outperform rating and a maintained price target of $125 by a reputable analyst like Luca Issi from RBC Capital is likely to instill confidence among investors about Moderna's future prospects. This positive outlook could lead to an upward movement in Moderna's stock price in the short term, as market participants react to the analyst's endorsement.